Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
NCT ID: NCT02039557
Last Updated: 2024-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
33 participants
OBSERVATIONAL
2014-05-01
2023-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Umbilical Cord Transplantation for the Elderly Population
NCT01484470
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
NCT00596999
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
NCT00737516
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
NCT00897260
Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)
NCT01235468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NiCord®/CordIn™ (omidubicel) transplanted
Anyone who signed the consent for this study received a NiCord®/CordIn™ (omidubicel) infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
NiCord®/CordIn™ (omidubicel)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NiCord®/CordIn™ (omidubicel)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gamida Cell ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Benioff Children's Hospital
Oakland, California, United States
Loyola University, Cardinal Bernardin Cancer Center
Maywood, Illinois, United States
Duke University Medical Center
Durham, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Vanderbilt
Nashville, Tennessee, United States
University Medical Center Utrecht
Utrecht, , Netherlands
National University Cancer Institute
Singapore, , Singapore
Singapore General Hospital
Singapore, , Singapore
University Hospital Vall D'Hebron
Barcelona, , Spain
Hospital Universitario La Fe
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GC P# 04.01.020/030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.